NO20006312L - Terapeutiske blandinger av selektive östrogenreseptor- modulatorer (SERM) og veksthormon sekretstimulerende middel (GHS) for behandling av muskuloskjelett skjörhet - Google Patents

Terapeutiske blandinger av selektive östrogenreseptor- modulatorer (SERM) og veksthormon sekretstimulerende middel (GHS) for behandling av muskuloskjelett skjörhet

Info

Publication number
NO20006312L
NO20006312L NO20006312A NO20006312A NO20006312L NO 20006312 L NO20006312 L NO 20006312L NO 20006312 A NO20006312 A NO 20006312A NO 20006312 A NO20006312 A NO 20006312A NO 20006312 L NO20006312 L NO 20006312L
Authority
NO
Norway
Prior art keywords
ghs
serms
treatment
growth hormone
fragility
Prior art date
Application number
NO20006312A
Other languages
English (en)
Other versions
NO20006312D0 (no
Inventor
Hua Zhu Ke
Lei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20006312D0 publication Critical patent/NO20006312D0/no
Publication of NO20006312L publication Critical patent/NO20006312L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen er rettet mot farmasøytiske kombinasjonsblandinger og fremgangsmåter inneholdende (-)-cis-6-fenyl-5-(4-(2-pyrrolidin-1-yl-etoksy)- fenyl)-5,6,7,8-tetrahydronaftalen-2-ol eller et farmasøytisk akesptabelt salt derav og2-amino-N-(2-(3a(R)-benzyl-2-metyl-3-okso-213,3a,4,6,7-heksahydropyra2olo- [4,3-c]pyridin-5-yl)-1(R)-benzyloksymetyl-2-oksoetyl)-isobutyramid eller et farma- søytisk akesptabelt salt derav, fremgangsmåter for anvendelse av slike blandinger og sett som inneholder slike blandinger. Blandingene kan anvendes for å be- handle muskelskjelett-skjørhet, inkludert osteoporose, osteoporotisk fraktur, lav benmasse, skjørhet, og lav muskelmasse.
NO20006312A 1998-06-16 2000-12-12 Terapeutiske blandinger av selektive östrogenreseptor- modulatorer (SERM) og veksthormon sekretstimulerende middel (GHS) for behandling av muskuloskjelett skjörhet NO20006312L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16
PCT/IB1999/001117 WO1999065486A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (2)

Publication Number Publication Date
NO20006312D0 NO20006312D0 (no) 2000-12-12
NO20006312L true NO20006312L (no) 2000-12-12

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006312A NO20006312L (no) 1998-06-16 2000-12-12 Terapeutiske blandinger av selektive östrogenreseptor- modulatorer (SERM) og veksthormon sekretstimulerende middel (GHS) for behandling av muskuloskjelett skjörhet

Country Status (30)

Country Link
EP (1) EP1087764A1 (no)
JP (1) JP2002518326A (no)
KR (1) KR20010052852A (no)
CN (1) CN1301160A (no)
AP (1) AP9901582A0 (no)
AR (1) AR018869A1 (no)
AU (1) AU4054799A (no)
BG (1) BG105041A (no)
BR (1) BR9911324A (no)
CA (1) CA2335134A1 (no)
CO (1) CO5070587A1 (no)
EA (1) EA200001186A1 (no)
GT (1) GT199900087A (no)
HN (1) HN1999000097A (no)
HR (1) HRP20000859A2 (no)
HU (1) HUP0102505A3 (no)
ID (1) ID27599A (no)
IL (1) IL138630A0 (no)
IS (1) IS5691A (no)
MA (1) MA26652A1 (no)
NO (1) NO20006312L (no)
OA (1) OA11505A (no)
PA (1) PA8475901A1 (no)
PE (1) PE20000646A1 (no)
PL (1) PL344981A1 (no)
SK (1) SK18912000A3 (no)
TN (1) TNSN99124A1 (no)
TR (1) TR200003544T2 (no)
WO (1) WO1999065486A1 (no)
ZA (1) ZA993975B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047735A2 (en) * 1999-02-08 2000-08-17 Mcgill University NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR ERRalpha
ES2274854T3 (es) 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
MA26652A1 (fr) 2004-12-20
HUP0102505A3 (en) 2002-12-28
PE20000646A1 (es) 2000-08-05
ID27599A (id) 2001-04-12
AP9901582A0 (en) 1999-06-30
SK18912000A3 (sk) 2001-10-08
GT199900087A (es) 2000-12-07
EP1087764A1 (en) 2001-04-04
OA11505A (en) 2004-05-07
HN1999000097A (es) 1999-11-03
BG105041A (en) 2001-08-31
TNSN99124A1 (fr) 2005-11-10
ZA993975B (en) 2000-12-15
PA8475901A1 (es) 2000-05-24
CA2335134A1 (en) 1999-12-23
EA200001186A1 (ru) 2001-06-25
AR018869A1 (es) 2001-12-12
IS5691A (is) 2000-10-27
TR200003544T2 (tr) 2001-04-20
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
JP2002518326A (ja) 2002-06-25
PL344981A1 (en) 2001-11-19
NO20006312D0 (no) 2000-12-12
CO5070587A1 (es) 2001-08-28
WO1999065486A1 (en) 1999-12-23
BR9911324A (pt) 2001-04-03
AU4054799A (en) 2000-01-05
CN1301160A (zh) 2001-06-27
KR20010052852A (ko) 2001-06-25
HRP20000859A2 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
NO20040331L (no) Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel
EP0911321A3 (en) Compounds for the treatment of osteoporosis
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
DE60037836D1 (de) ThiazoloÄ4,5-dÜpyrimidinverbindungen zur Behandlung von rheumathoider Arthritis
WO1998058911A3 (en) Prostaglandin agonists
NO20006312L (no) Terapeutiske blandinger av selektive östrogenreseptor- modulatorer (SERM) og veksthormon sekretstimulerende middel (GHS) for behandling av muskuloskjelett skjörhet
BG105125A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
NO20006381L (no) Terapeutiske kombinasjoner av (selektive) östrogenreseptormodulatorer (SERM) og veksthormonsekresjonsmidler
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
NZ504051A (en) Crystalline polymorphs of 1,3-di-cyclopropylmethyl-8-amino xanthine (cypamfylline), and the use of these compounds for treating PDE4 or TNF mediated diseases
NO980375L (no) Humant MP52 Arg protein
Schuind et al. Hyperostotic macrodactyly
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
Endo et al. The intramedullary gradual elongation nail: Application for femoral shaft non-union
TODANI A follow-up study of the subtrochanteric osteotomy for the treatment of the irreducible congenital dislocation of the hip
Garg et al. Long-term Functional Outcome in Fractures of the Lower End Radius in Young Adults Treated by Static External Fixator
Ikemoto et al. Treatment of Fracture-Dislocation of the Ankle
Whitman TREATMENT OF FRACTURES OF NECK OF FEMUR
UA28851A (uk) Спосіб оперативного лікування переломів дистального метаепіфізу великогомілкової кістки
Hajime et al. The Improvement of the Upper Extremity Function in Cerebral Palsy
Mizokami et al. Application of cast brac for fractures of the lower extremities
Fukushima et al. The Y-shaped Plate for the Fractures around the Joint
Zhuber et al. The Orthopedic Treatment of Patients with Apallic Syndrome

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application